Sélectionner la langue
ROR1
ROR1 Informations sur la molécule
| Nom anglais | Inactive tyrosine-protein kinase transmembrane receptor ROR1 | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 23 | Alias de la cible | EC 2.7.10.1，Inactive tyrosine-protein kinase transmembrane receptor ROR1，NTRKR1，ROR1，Receptor Tyrosine Kinase Like Orphan Receptor 1，Neurotrophic Tyrosine Kinase， Receptor-Related 1，DJ537F10.1，ROR-1 |
| Phase de R&D la plus avancée | Phase 3 Clinical | ||
| Nom anglais | Inactive tyrosine-protein kinase transmembrane receptor ROR1 |
| Alias de la cible | EC 2.7.10.1，Inactive tyrosine-protein kinase transmembrane receptor ROR1，NTRKR1，ROR1，Receptor Tyrosine Kinase Like Orphan Receptor 1，Neurotrophic Tyrosine Kinase， Receptor-Related 1，DJ537F10.1，ROR-1 |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 23 |
| Phase de R&D la plus avancée | Phase 3 Clinical |
ROR1 Liste de produits
- Attribut
Protein (21)Beads (1)Cell (1)
- Bibliothèque de produits
En ligne (23)
- Espèces
Human / Cynomolgus / Rhesus macaque (9)Mouse (4)Rat (1)Human (8)Canine (1)
- Étiquette
Fc Tag (3)His Tag (12)Fc Tag & Avi Tag (2)Avi Tag (1)His Tag & Avi Tag (2)- (2)Mouse IgG Fc Tag (1)
- Marqueur
Unconjugated (11)Biotin-labeled (5)- (2)FITC Labeled (2)PE Labeled (2)APC Labeled (1)
Ajouter au panier
Quantité totale23
- 1
- 2
- 3
ROR1Contexte de la molécule
Tyrosine-protein kinase transmembrane receptor ROR1 is also known as Neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), which belongs to the protein kinase superfamily or tyr protein kinase family or ROR subfamily. ROR1 contains 1 FZ (frizzled) domain, 1 Ig-like C2-type (immunoglobulin-like) domain, 1 kringle domain, 1 protein kinase domain. ROR1 is expressed at high levels during early embryonic development. The expression levels drop strongly around day 16 and there are only very low levels in adult tissues. Isoform Short is strongly expressed in fetal and adult CNS and in a variety of human cancers, including those originating from CNS or PNS neuroectoderm. ROR1 could interact with casein kinase 1 epsilon (CK1ε) to activate phosphoinositide 3-kinase-mediated AKT phosphorylation and cAMP-response-element-binding protein (CREB), which was associated with enhanced tumor-cell growth.
ROR1Alias de la molécule
ROR1,NTRKR1
Plateforme de commerce de projets d'anticorps
| Nom du projet | Phase du projet | Type de molécule | Source de molécule | Domain thérapeutique | Indication |
|---|---|---|---|---|---|
| ROR1 mAb - 01 | Lead | Monoclonal | Full Human | Hematological Malignancy,AutoImmunity | Solid tumor,Blood tumor |
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Zilovertamab vedotin | MK-2140; VLS-101 | Phase 3 Clinical | Velosbio Inc | Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Neoplasms; Neuroblastoma; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Richter's Syndrome; Sarcoma, Ewing; Stomach Neoplasms; Triple Negative Breast Neoplasms; Waldenstrom Macroglobulinemia | Details |
| B-013 | B-013; B013 | Phase 3 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd | Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms | Details |
| Zilovertamab | UC-961 | Phase 2 Clinical | University Of California San Diego | Breast Neoplasms; Immune System Diseases; Immunoproliferative Disorders; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Prostatic Neoplasms, Castration-Resistant | Details |
| EMB-07 | EMB-07 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Adenocarcinoma of Lung; Colorectal Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Neoplasms | Details |
| EB-DT-CAR-NK | EB-DT-CAR-NK | Phase 2 Clinical | Beijing Biotech | Breast Neoplasms; Triple Negative Breast Neoplasms | Details |
| NVG-222 | NVG-222 | Phase 2 Clinical | NovalGen Ltd | Hematologic Neoplasms; Neoplasms | Details |
| HDM-2005 | HDM2005; HDM-2005 | Phase 2 Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | Hematologic Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Neoplasms; Solid tumours | Details |
| Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Solid tumours | Details |
| HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
| anti-ROR1 CAR T-cell therapy (Fred Hutchinson Cancer Research Center/NCI) | Phase 1 Clinical | National Cancer Institute | Neoplasms | Details | |
| PB-004 | PB004; PBA-0405; PB004 PureBIKE; PB-004 | Phase 1 Clinical | Pure Biologics SA | Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| PRGN-3007 | PRGN-3007 | Phase 1 Clinical | Precigen Inc | Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours; Triple Negative Breast Neoplasms | Details |
| RD-14 | RD-14; RD-14-01; CTE001; RD14-01 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd | Breast Neoplasms; Lymphoma, Non-Hodgkin; Ovarian Neoplasms | Details |
| NEOK-001 | NEOK001; NEOK-001; ABL206; ABL-206 | Phase 1 Clinical | Abl Bio Inc | Solid tumours | Details |
| BR-111 | BR-111 | Phase 1 Clinical | Zhejiang BioRay Biopharmaceuticals Co Ltd | Neoplasms | Details |
| SYS-6005 | RB-164; RB164; SYS6005Y; SYS-6005 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Hematologic Neoplasms; Leukemia, B-Cell; Lymphoma, B-Cell; Neoplasms; Solid tumours | Details |
| TQB-2101 | TQB2101; TQB-2101 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Breast Neoplasms; Colorectal Neoplasms; Hematologic Neoplasms; Lung Neoplasms; Neoplasms | Details |
| ZPC-21 | ZPC-21; IM-1021 | Phase 1 Clinical | Zentalis Pharmaceuticals Inc | Hematologic Neoplasms; Neoplasms; Solid tumours | Details |
| BR-111A | BR-111A; BR111A; BR-111-A | Phase 1 Clinical | Zhejiang BioRay Biopharmaceuticals Co Ltd | Hematologic Diseases; Neoplasms; Solid tumours | Details |
| LYL-797 | LYL-797 | Phase 1 Clinical | Lyell Immunopharma Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours; Triple Negative Breast Neoplasms | Details |
| NVG-111 | NVG-111 | Phase 1 Clinical | NovalGen Ltd | Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Melanoma | Details |
| LCB-71 | CS-5001; LCB-71; ABL-202; ROR1-pPBD | Phase 1 Clinical | Abl Bio Inc, Legochem Biosciences Inc | Hematologic Neoplasms; Lymphoma; Lymphoma, B-Cell; Solid tumours | Details |
| SIM-201 | SIM-201; SIM-0201 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd | Solid tumours | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques
Partager vers :